Sharlene Litchy

2.4k total citations
26 papers, 1.9k citations indexed

About

Sharlene Litchy is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sharlene Litchy has authored 26 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Pathology and Forensic Medicine and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sharlene Litchy's work include Lung Cancer Diagnosis and Treatment (8 papers), Lymphoma Diagnosis and Treatment (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Sharlene Litchy is often cited by papers focused on Lung Cancer Diagnosis and Treatment (8 papers), Lymphoma Diagnosis and Treatment (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Sharlene Litchy collaborates with scholars based in United States. Sharlene Litchy's co-authors include John D. Hainsworth, F. Anthony Greco, Howard A. Burris, Lisa H. Morrissey, Daniel C. Scullin, John H. Barton, James E. Bradof, Paul Richards, James D. Bearden and Don W. Shaffer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Sharlene Litchy

24 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sharlene Litchy United States	15	1.2k	1.0k	749	356	322	26	1.9k
Lisa H. Morrissey United States	14	768 0.6×	859 0.8×	372 0.5×	238 0.7×	179 0.6×	27	1.4k
Daniel C. Scullin United States	13	650 0.5×	586 0.6×	362 0.5×	233 0.7×	184 0.6×	23	1.1k
Tore Halvorsen Norway	23	312 0.3×	655 0.6×	382 0.5×	116 0.3×	126 0.4×	44	2.0k
C.R. Freeman Norway	5	1.6k 1.3×	870 0.8×	245 0.3×	92 0.3×	197 0.6×	9	2.0k
Diego Villa Canada	26	2.0k 1.7×	1.2k 1.2×	721 1.0×	195 0.5×	286 0.9×	147	2.5k
Patricia T. Greipp United States	27	407 0.3×	631 0.6×	437 0.6×	171 0.5×	292 0.9×	142	2.4k
Fabrizio Lombardi Italy	13	683 0.6×	749 0.7×	428 0.6×	107 0.3×	79 0.2×	26	1.7k
David S. Viswanatha United States	32	1.8k 1.5×	1.1k 1.1×	966 1.3×	51 0.1×	504 1.6×	133	3.6k
Hye Jin Kang South Korea	26	905 0.8×	822 0.8×	254 0.3×	133 0.4×	191 0.6×	120	1.8k
Maurizio Martelli Italy	20	1.2k 1.0×	641 0.6×	396 0.5×	124 0.3×	115 0.4×	101	1.6k

Countries citing papers authored by Sharlene Litchy

Since Specialization

Citations

This map shows the geographic impact of Sharlene Litchy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharlene Litchy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharlene Litchy more than expected).

Fields of papers citing papers by Sharlene Litchy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharlene Litchy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharlene Litchy. The network helps show where Sharlene Litchy may publish in the future.

Co-authorship network of co-authors of Sharlene Litchy

This figure shows the co-authorship network connecting the top 25 collaborators of Sharlene Litchy. A scholar is included among the top collaborators of Sharlene Litchy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharlene Litchy. Sharlene Litchy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Raefsky, Eric, F. Anthony Greco, David R. Spigel, et al.. (2007). First-line treatment with single agent rituximab, followed by maintenance rituximab plus anti-idiotype Id-KLH active immunotherapy vaccine (FavId) in patients (pts) with low-grade non-Hodgkin lymphoma (NHL): Preliminary results of a phase II trial. Journal of Clinical Oncology. 25(18_suppl). 8080–8080.

2.

Spigel, David R., John D. Hainsworth, Denise A. Yardley, et al.. (2006). Preoperative gemcitabine (G) and docetaxel (D) in patients (pts) with stage IB, II, or III non-small cell lung cancer (NSCLC): A phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 24(18_suppl). 17007–17007. 1 indexed citations

3.

Hainsworth, John D., et al.. (2006). Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Patients with Advanced Transitional Cell Carcinoma of the Urothelium. The Journal of Urology. 175(2). 483–484. 1 indexed citations

4.

Hainsworth, John D., David R. Spigel, Sharlene Litchy, & F. Anthony Greco. (2006). Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study. Journal of Clinical Oncology. 24(22). 3548–3554. 146 indexed citations

5.

McKay, Charles, John D. Hainsworth, David R. Spigel, et al.. (2005). Adjuvant paclitaxel (P)/carboplatin (C) in stages I, II non-small cell lung cancer (NSCLC): Comparison of two schedules in phase II trials by the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 23(16_suppl). 7123–7123. 1 indexed citations

6.

Hainsworth, John D., David R. Spigel, Eric Raefsky, et al.. (2005). Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site. Cancer. 104(9). 1992–1997. 25 indexed citations

7.

Hainsworth, John D., Anthony A. Meluch, Sharlene Litchy, et al.. (2005). Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 103(11). 2298–2303. 39 indexed citations

8.

Spigel, David R., John D. Hainsworth, Dana S. Thompson, et al.. (2005). Paclitaxel/carboplatin/etoposide (PCE) therapy for advanced poorly differentiated neuroendocrine (PDNE) carcinoma: A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology. 23(16_suppl). 4058–4058. 1 indexed citations

9.

Hainsworth, John D., et al.. (2005). Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 23(6). 1088–1095. 253 indexed citations

10.

Hainsworth, John D., James R. Gray, Sharlene Litchy, et al.. (2004). A Phase II Trial of Preoperative Concurrent Radiation Therapy and Weekly Paclitaxel/Carboplatin for Patients with Locally Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 6(1). 33–42. 9 indexed citations

11.

Greco, F. Anthony, Sharlene Litchy, Robert C. Hermann, et al.. (2004). Carcinoma of unknown primary site with unfavorable characteristics: Survival of 396 patients after treatment with five consecutive phase II trials by the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 22(14_suppl). 4186–4186. 2 indexed citations

12.

Greco, F. Anthony, Sharlene Litchy, Robert C. Hermann, et al.. (2004). Carcinoma of unknown primary site with unfavorable characteristics: Survival of 396 patients after treatment with five consecutive phase II trials by the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 22(14_suppl). 4186–4186. 3 indexed citations

13.

Greco, F. Anthony, Gladys Rodriguez, Don W. Shaffer, et al.. (2004). Carcinoma of Unknown Primary Site: Sequential Treatment with Paclitaxel/Carboplatin/Etoposide and Gemcitabine/Irinotecan: A Minnie Pearl Cancer Research Network Phase II Trial. The Oncologist. 9(6). 644–652. 41 indexed citations

14.

Hainsworth, John D., et al.. (2003). First-Line Treatment with Brief-Duration Chemotherapy Plus Rituximab in Elderly Patients with Intermediate-Grade Non-Hodgkin's Lymphoma: Phase II Trial. Clinical Lymphoma. 4(1). 36–42. 29 indexed citations

15.

Greco, F. Anthony, Howard A. Burris, Sharlene Litchy, et al.. (2002). Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Unknown Primary Site: A Minnie Pearl Cancer Research Network Study. Journal of Clinical Oncology. 20(6). 1651–1656. 85 indexed citations

16.

Greco, F. Anthony, Howard A. Burris, James R. Gray, et al.. (2001). Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma. Cancer. 92(8). 2142–2147. 7 indexed citations

17.

Hainsworth, John D., Howard A. Burris, Sharlene Litchy, et al.. (2000). Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. Cancer. 89(2). 328–333. 123 indexed citations

18.

Hainsworth, John D., Howard A. Burris, Lisa H. Morrissey, et al.. (2000). Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 95(10). 3052–3056. 200 indexed citations

19.

Hainsworth, John D., Howard A. Burris, Sharlene Litchy, et al.. (2000). Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients. Cancer. 88(6). 1353–1358. 36 indexed citations

20.

Hainsworth, John D., Howard A. Burris, Lisa H. Morrissey, et al.. (2000). Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 95(10). 3052–3056. 182 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact